A CASE REPORT OF BILATERAL RENAL AND SPLENIC INFARCTS IN SEVERE COVID-19 WHILE ON PROPHYLACTIC HEPARIN

por LIVITZ, B., MILETIC, N., GO, R.
Publicado 2022

A population-based study of large granular lymphocyte leukemia

por Shah, M V, Hook, C C, Call, T G, Go, R S
Publicado 2016

Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set

por Goyal, G, Bartley, A C, Patnaik, M M, Litzow, M R, Al-Kali, A, Go, R S
Publicado 2017

RACIAL/ETHNIC DISPARITIES ON INFLAMMATORY MARKERS IN SEVERE COVID-19 PNEUMONIA

por GO, R., NYIRENDA, T., BOJARIAN, M., KARIMIHOSSEINI, D., KIM, K., RAHIM, M., GO, A., HAN, Z., SPERBER, S., GUPTA, A.
Publicado 2022

Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury

por Kawase, Wataru, Kurotaki, Daisuke, Suzuki, Yuta, Ishihara, Hiroshi, Ban, Tatsuma, Sato, Go R., Ichikawa, Juri, Yanai, Hideyuki, Taniguchi, Tadatsugu, Tsukahara, Kappei, Tamura, Tomohiko
Publicado 2021

P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVA...

por Jaeger, U., Broome, C., Go, R., Patriarca, A., Roeth, A., Chang, Q., Weedin, N., Adams, P., Cahir-McFarland, E., Kroon, H.-A.
Publicado 2022

P1139: A POPULATION-BASED STUDY OF ISOLATED ADULT PULMONARY LANGERHANS CELL HISTIOCYTOSIS IN THE UNITED STATES: 2010-2017

por Ruan, G., Abeykoon, J., Hazim, A., Ravindran, A., Rech, K., Young, J., Cox, C., Ryu, J., Koster, M., Tobin, O., Shah, M., Bennani, N., Vassallo, R., Goyal, G., Go, R.
Publicado 2022

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

por Ravindran, A, Bartley, A C, Holton, S J, Gonsalves, W I, Kapoor, P, Siddiqui, M A, Hashmi, S K, Marshall, A L, Ashrani, A A, Dispenzieri, A, Kyle, R A, Rajkumar, S V, Go, R S
Publicado 2016

ABO BLOOD TYPES AND INFLAMMATORY MARKERS IN COVID-19 PNEUMONIA

por GO, R., SARFRAZ, K., NYIRENDA, T., GADI, N., RAHIM, M., KIM, K., PHILIP, L., BHEEMAN, C., YOUSAFZAI, O., BOJARIAN, M., KARIMIHOSSEINI, D., KARPEL, D., PATEL, P., SHAH, R., SIMONE, M., MINOCK, M., ROSE, K., OMIDVARI, K.
Publicado 2022

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2017

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

por Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Publicado 2015

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

por Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2016

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP

por Abdallah, N., Dispenzieri, A., Muchtar, E., Buadi, F., Kapoor, P., Lacy, M., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Leung, N., Dingli, D., Go, R., Lin, Y., Gonsalves, W., Binder, M., Kourelis, T., Warsame, R., Kyle, R., Rajkumar, S., Gertz, M., Kumar, S.
Publicado 2022

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

por Warsame, R, Kumar, S K, Gertz, M A, Lacy, M Q, Buadi, F K, Hayman, S R, Leung, N, Dingli, D, Lust, J A, Ketterling, R P, Lin, Y, Russell, S, Hwa, L, Kapoor, P, Go, R S, Zeldenrust, S R, Kyle, R A, Rajkumar, S V, Dispenzieri, A
Publicado 2015

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE

por Vaxman, I., Kumar, S., buadi, F., Lacy, M., Dingli, D., Fonder, A., Hobbs, M., Hayman, S., hwa, L. Y., Kouralis, T., Warsame, R., Muchtar, E., Nelson, L., Kapoor, P., Grogan, M., Go, R., Gonsalves, W., Siddiqi, M., Robert, K., Rajkumar, V., Gertz, M., Dispenzieri, A.
Publicado 2022

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

por Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hayman, S., Kourelis, T., Warsame, R., Hwa, Y., Fonder, A., Hobbs, M., Muchtar, E., Leung, N., Kapoor, P., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Publicado 2023

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

por Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado 2016

Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease

por Ban, Tatsuma, Kikuchi, Masako, Sato, Go R., Manabe, Akio, Tagata, Noriko, Harita, Kayo, Nishiyama, Akira, Nishimura, Kenichi, Yoshimi, Ryusuke, Kirino, Yohei, Yanai, Hideyuki, Matsumoto, Yoshiko, Suzuki, Shuichi, Hihara, Hiroe, Ito, Masashi, Tsukahara, Kappei, Yoshimatsu, Kentaro, Yamamoto, Tadashi, Taniguchi, Tadatsugu, Nakajima, Hideaki, Ito, Shuichi, Tamura, Tomohiko
Publicado 2021

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

por Binder, M, Rajkumar, S V, Ketterling, R P, Greipp, P T, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado 2017

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

por Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Publicado 2021